Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

CD147: A Novel Modulator of Inflammatory and Immune Disorders

Author(s): X. Zhu, Z. Song, S. Zhang, A. Nanda and G. Li

Volume 21 , Issue 19 , 2014

Page: [2138 - 2145] Pages: 8

DOI: 10.2174/0929867321666131227163352

Price: $65

Abstract

CD147, a transmembrane glycoprotein, is expressed on all leukocytes, platelets, and endothelial cells. It has been implicated in a variety of physiological and pathological activities through interacting with multiple partners, including cyclophilins, monocarboxylate transporters, Caveolin-1, and integrins. While CD147 is best known as a potent inducer of extracellular matrix metalloproteinases (hence also called EMMPRIN), it can also function as a key mediator of inflammatory and immune responses. Increased expression of CD147 has been implicated in the pathogenesis of a number of diseases, such as asthma-mediated lung inflammation, rheumatoid arthritis, multiple sclerosis, myocardial infarction and ischemic stroke. Therapeutic targeting of CD147 has yielded encouraging effects in a number of experimental models of human diseases, suggesting CD147 as an attractive target for treatment of inflammation-related diseases. Here we review the current understanding of CD147 expression and functions in inflammatory and immune responses and potential implications for treatment of inflammatory disorders.

Keywords: CD147, MMP, cyclophilin, MCT, integrin, inflammation, leukocyte, platelet.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy